AELIS FARMA’s Post

Another example of combination therapy success from KINNOV THERAPEUTICS, a spin-off of Greenpharma S.A.S. ! Check out our new product Oncombo for oncology using drug association. https://lnkd.in/eRtRdR-b #drugcombination #drugassociation #therapy #screening #compoundlibrary #oncology #combinationtherapy

🔬 From Weight Loss to Addiction Busting: Ozempic's Unexpected Superpowers! 💪 New research published in Addiction journal is turning heads faster than you can say 'semaglutide'! 🤯 Key findings: 40% lower opioid overdose rates 50% reduced alcohol intoxication 500,000+ people studied Who knew those trendy weight-loss shots could be secret weapons against the opioid epidemic? 🦸♀️💉 But hold your horses, folks! As Prof. Fares Qeadan from Loyola University Chicago reminds us, we need more randomized controlled trials before we pop the champagne (responsibly, of course 😉). With 81,000+ opioid-related deaths in the US in 2023, could GLP-1 drugs be the plot twist we've been waiting for? 🎬 Novo Nordisk and Eli Lilly, take a bow – your Ozempic, Wegovy, and Mounjaro might just be the multitasking marvels of modern medicine! 🏆 #HealthcareInnovation #AddictionTreatment #MedicalBreakthrough #ObesityMedicine #PharmaTech #DataDrivenHealth #ClinicalResearch

🍃KRATOM is viewed by NIDA National Institute of Drug Abuse as part of the solution to the opioid crisis and not the problem. 🍃Kratom, Director of NIDA National Institute on Drug Abuse has a positive view on kratom. 🍃to the tune of $100 Million dollars, the amount of research spending on kratom. 🍃She believes it’s part of the solution for many. So much so that in her private lab at NIDA she is doing research on KRATOM. 🍃🍃Dec 13 2023 she did a congressional briefing on kratom and told congress to regulate it as other supplements.🍃🍃 NIDA on Kratom addiction safety profile. 2021 NIDA DIRECTOR’S REPORT Nora D. Volkow, M.D. Dir National Institute Drug Abuse. 2 links in this post “initial findings indicate mitragynine and 7-hydroxymitragynine are not rewarding in ICSS procedure. present results suggest kratom alkaloids do not have abuse potential.” https://lnkd.in/gfRDMve3 Here’s the actual scientific paper that NIDA Dir Dr Volkow was referring to @highlight https://lnkd.in/gFp8y79

🍃Kratom, Director of NIDA National Institute on Drug Abuse has a positive view on kratom. 🍃to the tune of $100 Million dollars, the amount of research spending on kratom. 🍃She believes it’s part of the solution for many. So much so that in her private lab at NIDA she is doing research on KRATOM. 🍃🍃Dec 13 2023 she did a congressional briefing on kratom and told congress to regulate it as other supplements.🍃🍃 Kratom addictive? NIDA on Kratom addiction safety profile. 2021 NIDA DIRECTOR’S REPORT Nora D. Volkow, M.D. Dir National Institute Drug Abuse. 2 links in this post “initial findings indicate mitragynine and 7-hydroxymitragynine are not rewarding in ICSS procedure. present results suggest kratom alkaloids do not have abuse potential.” https://lnkd.in/gfRDMve3 Here’s the actual scientific paper that NIDA Dir Dr Volkow was referring to https://lnkd.in/gFp8y79 ‪

🍃Kratom, Director of NIDA National Institute on Drug Abuse has a positive view on kratom. 🍃to the tune of $100 Million dollars, the amount of research spending on kratom. 🍃She believes it’s part of the solution for many. So much so that in her private lab at NIDA she is doing research on KRATOM. 🍃🍃Dec 13 2023 she did a congressional briefing on kratom and told congress to regulate it as other supplements.🍃🍃 Kratom addictive? NIDA on Kratom addiction safety profile. 2021 NIDA DIRECTOR’S REPORT Nora D. Volkow, M.D. Dir National Institute Drug Abuse. 2 links in this post “initial findings indicate mitragynine and 7-hydroxymitragynine are not rewarding in ICSS procedure. present results suggest kratom alkaloids do not have abuse potential.” https://lnkd.in/gfRDMve3 Here’s the actual scientific paper that NIDA Dir Dr Volkow was referring to ‪ https://lnkd.in/gFp8y79

🍃Kratom, Director of NIDA National Institute on Drug Abuse has a positive view on kratom. 🍃to the tune of $100 Million dollars, the amount of research spending on kratom. 🍃She believes it’s part of the solution for many. So much so that in her private lab at NIDA she is doing research on KRATOM. 🍃🍃Dec 13 2023 she did a congressional briefing on kratom and told congress to regulate it as other supplements.🍃🍃 Kratom addictive? NIDA on Kratom addiction safety profile. 2021 NIDA DIRECTOR’S REPORT Nora D. Volkow, M.D. Dir National Institute Drug Abuse. 2 links in this post “initial findings indicate mitragynine and 7-hydroxymitragynine are not rewarding in ICSS procedure. present results suggest kratom alkaloids do not have abuse potential.” https://lnkd.in/gfRDMve3 Here’s the actual scientific paper that NIDA Dir Dr Volkow was referring to https://lnkd.in/gFp8y79 ‪

🍃Kratom, Director of NIDA National Institute on Drug Abuse has a positive view on kratom. 🍃to the tune of $100 Million dollars, the amount of research spending on kratom. 🍃She believes it’s part of the solution for many. So much so that in her private lab at NIDA she is doing research on KRATOM. 🍃🍃Dec 13 2023 she did a congressional briefing on kratom and told congress to regulate it as other supplements.🍃🍃 Kratom addictive? NIDA on Kratom addiction safety profile. 2021 NIDA DIRECTOR’S REPORT Nora D. Volkow, M.D. Dir National Institute Drug Abuse. 2 links in this post “initial findings indicate mitragynine and 7-hydroxymitragynine are not rewarding in ICSS procedure. present results suggest kratom alkaloids do not have abuse potential.” https://lnkd.in/gfRDMve3 Here’s the actual scientific paper that NIDA Dir Dr Volkow was referring to https://lnkd.in/gFp8y79 ‪

Psychedelic substances have significant potential in substance use and mental health disorder treatment. Ibogaine has been a subject of both academic and professional interest for me. During Georgetown University Addiction Policy & Practice Program, I focused on this topic for one of my final projects that was taught by NIDA's deputy director, Wilson Compton. Ibogaine shows promise in treating bipolar disorder, opioid use disorder, and it was even explored as a potential ARV therapy for HIV treatment. However, its use may lead to torsade de pointes, a potentially lethal heart condition. NIDA funded research aimed at eliminating the psychedelic properties and cardiovascular complications of Ibogaine to make it viable for opioid use disorder treatment. It's encouraging to hear about progress, but I think further research is necessary. The illegality of the substance disrupts this process. Countries like Finland, New Zealand, and Uruguay have legalized possession, paving the way for potential advancements in research and practice.

🚨 Understanding Xylazine: An Emerging Threat in Canada 🚨 At Spectrum MDX, we strive to keep our clients informed about critical public health trends. Our latest blog post dives deep into the rise of xylazine in Canada and its implications for substance abuse clinics and rehab centers. Learn about: 🔹 Key Findings: Significant rise in xylazine detections since 2019. 🔹 Health Risks: Central nervous system depression, respiratory issues, and cardiovascular effects. 🔹 Treatment Considerations: Monitoring, naloxone administration, and comprehensive care. Stay ahead in providing the best care. Contact us to discover how our custom-made testing cups can enhance your treatment programs. 🔗 Read the full article: https://lnkd.in/encXPiha #PublicHealth #Xylazine #AddictionTreatment #HealthcareInnovation #SpectrumMDX #DrugAwareness #HealthcareProfessionals #PatientCare #OpioidCrisis #DrugSafety #HealthCanada #SubstanceAbusePrevention #AddictionRecovery #PublicSafety #EmergingThreats #ClinicalSupport #HealthcareSolutions #MedicalInnovation #Toxicology #CommunityHealth #DrugEpidemic #HealthEducation #MedicalResearch #HealthcareUpdates #AddictionSupport

We often discuss the medical and therapeutic interventions necessary in substance use management and harm reduction, but emotional components like empathy, love, and understanding also play an important role. When we are working with patients, we make it a point to incorporate this facet of care because feelings of dependency on substances are more than just physiological ailments. “The health outcomes of substance use aren’t linear connections; they are also created and mediated by our socialized views about drugs themselves and the people who use them,” says Beth Meyerson, PhD, director of the Harm Reduction Research Lab in the Arizona University College of Medicine at Tucson. In other words, the stigma that comes with substance use is a complicated barrier to break down. Dating back to the early 1900s, the demonizing of certain narcotic drugs led to the categorization of illicit drugs  – opiates, cocaine and marijuana – as a moral issue instead of a health issue. Meyerson’s lab at UArizona is working on a “patient-empowered, trauma-informed methadone treatment protocol” that strives to put the emotions of its participants first and reduce instances of relapse and overdoses. Read more about the UArizona Project Here: #harmreduction #emotionalintelligence #substanceusemanagement #addictiontreatment #addictionscience https://lnkd.in/g25X4gag